Rosa I. Gallagher

1.8k total citations
27 papers, 808 citations indexed

About

Rosa I. Gallagher is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Rosa I. Gallagher has authored 27 papers receiving a total of 808 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 14 papers in Oncology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Rosa I. Gallagher's work include HER2/EGFR in Cancer Research (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Advanced Biosensing Techniques and Applications (4 papers). Rosa I. Gallagher is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Advanced Biosensing Techniques and Applications (4 papers). Rosa I. Gallagher collaborates with scholars based in United States, China and Austria. Rosa I. Gallagher's co-authors include Julia Wulfkuhle, Virginia Espina, Emanuel F. Petricoin, Lance A. Liotta, Emanuel F. Petricoin, H. Kim Lyerly, Xiaoyi Yang, Sumin Zhao, Lei-Hua Liu and Sarah Bacus and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Rosa I. Gallagher

25 papers receiving 798 citations

Peers

Rosa I. Gallagher
Shaoyan Xi China
Mark Gustavson United States
Brigid C. Browne Ireland
Kristina von Boguslawski Finland
Josep-Lluís Parra Spain
Zachary A. Kohutek United States
Gary Box United Kingdom
Elizabeth Cohen–Jonathan France
Rosalin Mishra United States
Maria F. Camargo United States
Shaoyan Xi China
Rosa I. Gallagher
Citations per year, relative to Rosa I. Gallagher Rosa I. Gallagher (= 1×) peers Shaoyan Xi

Countries citing papers authored by Rosa I. Gallagher

Since Specialization
Citations

This map shows the geographic impact of Rosa I. Gallagher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosa I. Gallagher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosa I. Gallagher more than expected).

Fields of papers citing papers by Rosa I. Gallagher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rosa I. Gallagher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosa I. Gallagher. The network helps show where Rosa I. Gallagher may publish in the future.

Co-authorship network of co-authors of Rosa I. Gallagher

This figure shows the co-authorship network connecting the top 25 collaborators of Rosa I. Gallagher. A scholar is included among the top collaborators of Rosa I. Gallagher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosa I. Gallagher. Rosa I. Gallagher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zahavi, David J., Rossin Erbe, Yongwei Zhang, et al.. (2023). Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance. Cancer Biology & Therapy. 24(1). 2269637–2269637. 1 indexed citations
3.
Okumura, Kōichi, Rosa I. Gallagher, Julia Wulfkuhle, et al.. (2022). Synthesis of 2-oxoquinoline derivatives as dual pim and mTORC protein kinase inhibitors. Medicinal Chemistry Research. 31(7). 1154–1175. 1 indexed citations
4.
González-Ericsson, Paula I., Rosa I. Gallagher, Xiaopeng Sun, et al.. (2021). Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. Clinical Cancer Research. 27(19). 5299–5306. 54 indexed citations
5.
Shi, Zhen, Julia Wulfkuhle, Małgorzata Nowicka, et al.. (2021). Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. Clinical Cancer Research. 28(5). 993–1003. 31 indexed citations
6.
Wolf, Denise M., Christina Yau, Julia Wulfkuhle, et al.. (2020). Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. npj Breast Cancer. 6(1). 48–48. 25 indexed citations
7.
Cruickshanks, Nichola, Ying Zhang, Myron Gibert, et al.. (2018). Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clinical Cancer Research. 25(2). 663–673. 35 indexed citations
8.
Wulfkuhle, Julia, Denise M. Wolf, Christina Yau, et al.. (2018). Phosphorylation of AKT kinase substrates to predict response to the AKT inhibitor MK2206 in the I-SPY 2 trial in both HER2- and HER2+ patients.. Journal of Clinical Oncology. 36(15_suppl). 12099–12099. 1 indexed citations
9.
Zhang, Ying, Nichola Cruickshanks, Fang Yuan, et al.. (2017). Targetable T-type Calcium Channels Drive Glioblastoma. Cancer Research. 77(13). 3479–3490. 81 indexed citations
10.
Jayappa, Kallesh D., Craig A. Portell, Vicki L. Gordon, et al.. (2017). Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Advances. 1(14). 933–946. 81 indexed citations
11.
Gordon, Melita A., Nicholas C. D’Amato, Haihua Gu, et al.. (2017). Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. Molecular Cancer Therapeutics. 16(7). 1389–1400. 41 indexed citations
12.
Naeem, Aisha, Erika Parasido, Deborah L. Berry, et al.. (2017). Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells. Oncotarget. 9(2). 2193–2207. 16 indexed citations
13.
Wulfkuhle, Julia, Christina Yau, Denise M. Wolf, et al.. (2015). Protein activation mapping and exploratory predictive markers for pCR in triple-negative breast cancer patients treated with neratinib in the I-SPY 2 TRIAL.. Journal of Clinical Oncology. 33(15_suppl). 1085–1085. 2 indexed citations
14.
Jameson, Gayle, Emanuel F. Petricoin, Jasgit C. Sachdev, et al.. (2014). A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Research and Treatment. 147(3). 579–588. 57 indexed citations
15.
Gallagher, Rosa I. & Virginia Espina. (2014). Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine. Molecular Diagnosis & Therapy. 18(6). 619–630. 32 indexed citations
16.
Xia, Wenle, Sumin Zhao, Lei-Hua Liu, et al.. (2013). An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Research. 15(5). R85–R85. 113 indexed citations
17.
Gallagher, Rosa I., Alessandra Silvestri, Emanuel F. Petricoin, Lance A. Liotta, & Virginia Espina. (2011). Reverse Phase Protein Microarrays: Fluorometric and Colorimetric Detection. Methods in molecular biology. 723. 275–301. 13 indexed citations
18.
Gallagher, Rosa I., et al.. (2011). Laser Capture Microdissection: ArcturusXT Infrared Capture and UV Cutting Methods. Methods in molecular biology. 823. 157–178. 24 indexed citations
19.
Nagarwala, Yasir M., Virginia Espina, L. A. Liotta, et al.. (2011). Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.. Journal of Clinical Oncology. 29(15_suppl). 506–506. 37 indexed citations
20.
Espina, Virginia, Brian D. Mariani, Rosa I. Gallagher, et al.. (2010). Malignant Precursor Cells Pre-Exist in Human Breast DCIS and Require Autophagy for Survival. PLoS ONE. 5(4). e10240–e10240. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shaoyan Xi Breakdown of academic impact, for papers by Mark Gustavson Breakdown of academic impact, for papers by Brigid C. Browne Breakdown of academic impact, for papers by Kristina von Boguslawski Breakdown of academic impact, for papers by Josep-Lluís Parra Breakdown of academic impact, for papers by Zachary A. Kohutek Breakdown of academic impact, for papers by Gary Box Breakdown of academic impact, for papers by Elizabeth Cohen–Jonathan Breakdown of academic impact, for papers by Rosalin Mishra Breakdown of academic impact, for papers by Maria F. Camargo
Rankless by CCL
2026